OctoPlus N.V. signed a new drug delivery technology evaluation contract with an undisclosed European biotech company. This is the seventh client for which OctoPlus will work on a controlled release formulation. Under the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the client’s active ingredient with OctoPlus’ drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, man...